onc-392
mAbexperimental
Clinical trial activity
4 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04140526)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Adenoid Cystic · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Salivary Gland Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314987 ↗
- ChEMBLCHEMBL4594486 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05682443 | Phase 1/Phase 2 (Phase 2) | Dec 6, 2023 | Columbia University, New York University, OncoC4, Inc., Prostate Cancer Clinical Trials Consortium |
| NCT05671510 | Phase 3 | Jun 28, 2023 | Biontech, Ohio State University, OncoC4, Inc., University of California, Davis |
| NCT05446298 | Phase 2 | Dec 30, 2022 | GOG Foundation, Inc., Merck, OncoC4, Inc. |
| NCT04140526 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | OncoImmune, Inc., University of Maryland |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoC4, Inc. | For profit | 3 | 3 | 2 | 2022 |
| Biontech | For profit | 1 | 0 | 1 | 2023 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| OncoImmune, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Prostate Cancer Clinical Trials Consortium | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2020 |
11 organizations
Page 1 / 1